All In Biotech

Drug Trial Radar · NCT06265727

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Apr 1, 2024

Primary completion

Jan 16, 2027

Study completion Jan 27, 2027

Sponsor

Lead sponsor
Corbus Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.

Conditions

  • Solid Tumor, Adult

Interventions

  • CRB-701Drug

    Nectin-4 targeted Antibody Drug Conjugate (ADC)

  • Anti-PD-1Drug

    checkpoint inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To confirm the safety and tolerability and determine MTD and PADR for CRB-701Time frame: 21 days
  2. Part B & C: To evaluate efficacy in terms of Objective Response Rate (ORR)Time frame: Up to 6 months

Locations

41 sites in 7 countries. Site status is shown where the registry gives one.

  • O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham

    Birmingham, Alabama · Recruiting

  • City of Hope Cancer Center

    Duarte, California · Recruiting

  • Moores Cancer Centre at UC San Diego Health

    San Diego, California · Recruiting

  • Helen Diller Family Comprehensive Cancer Center - UCSF

    San Francisco, California · Recruiting

  • Rocky Mountain Cancer Centres

    Denver, Colorado · Active not recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Hope and Healing Cancer Center

    Hinsdale, Illinois · Active not recruiting

  • Dana-Faber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Nebraska Hematology Oncology

    Lincoln, Nebraska · Active not recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Active not recruiting

  • Texas Oncology

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Active not recruiting

  • Fred Hutchinson Cancer Center at University of Washington

    Seattle, Washington · Recruiting

  • ICM-Val d'Aurelle

    Montpellier, France · Recruiting

  • CHU de Poitiers

    Poitiers, France · Recruiting

  • Institut de Cancerologie de l'Ouest

    Saint-Herblain, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Careggi University Hospital

    Florence, Italy · Recruiting

  • European Institute of Oncology IRCCS

    Milan, Italy · Recruiting

  • Fondazione Policlinico Gemelli, IRCCS

    Rome, Italy · Recruiting

  • Centro Richerche Cliniche di Verona

    Verona, Italy · Recruiting

  • Institute of Oncology/ARENSIA Exploratory Medicine

    Chisinau, Moldova · Withdrawn

  • Aresnsia Research Clinic Bucharest

    Bucharest, Romania · Recruiting

  • Aresnsia Research Clinic Cluj-Napoca

    Cluj-Napoca, Romania · Recruiting

  • Centrul de Oncologie Sf. Nectarie

    Iași, Romania · Recruiting

  • Centrul de Oncologie Euroclinic

    Iași, Romania · Recruiting

  • Barcelona IOB Hospital Quironsalud (NEXT)

    Barcelona, Spain · Recruiting

  • Vall d-Hebron Institut d'Oncologia

    Barcelona, Spain · Recruiting

  • Fundacion Jimenez Diaz (START)

    Madrid, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain · Recruiting

  • University of Birmingham NHS Foundation Trust

    Birmingham, United Kingdom · Recruiting

  • University of Cambridge NHS Foundation Trust

    Cambridge, United Kingdom · Recruiting

  • Velindre Cancer Centre

    Cardiff, United Kingdom · Recruiting

  • Leeds University Hospitals NHS Trust

    Leeds, United Kingdom · Recruiting

  • Guy's and St Thomas' Clinical Research Facility

    London, United Kingdom · Recruiting

  • Imperial Experimental Cancer Medicine Centre

    London, United Kingdom · Recruiting

  • The Christie Hospital

    Manchester, United Kingdom · Recruiting

  • University of Liverpool - Clatterbridge Medical Centre

    Metropolitan Borough of Wirral, United Kingdom · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.